Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor versus placebo in unresectable advanced dedifferentiated liposarcoma
MOH_2018-05-10_002371Phase 3Not yet recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Liposarcoma comparing Selinexor with Placebo (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on MOH_2018-05-10_002371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-10_002371.